LB Pharmaceuticals initiates Phase 2 trial of LB-102 [Yahoo! Finance]
LB Pharmaceuticals Inc (LBRX)
Company Research
Source: Yahoo! Finance
LB-102, a novel, once-daily, oral investigational small molecule, is a potent and selective antagonist of D2, D3, and 5HT7 receptors that is being advanced as a potential first benzamide antipsychotic in the U.S. for the treatment of neuropsychiatric disorders. Anna Eramo, Chief Medical Officer of LB Pharmaceuticals added, “We believe LB-102's pharmacologic profile, including selective D2, D3, and 5HT7 receptor antagonism and favorable tolerability observed in prior clinical trials, aligns well with the critical unmet needs in bipolar depression. Significant opportunity exists for new therapies that can offer early onset of effect, reduced side effects such as sedation and EPS (including akathisia), and improvement in anhedonia and cognitive deficits, all of which can impact a patient's ability to function.” Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio
Show less
Read more
Impact Snapshot
Event Time:
LBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LBRX alerts
High impacting LB Pharmaceuticals Inc news events
Weekly update
A roundup of the hottest topics
LBRX
News
- LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development ProgramGlobeNewswire
- LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General CounselGlobeNewswire
- LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- LB Pharmaceuticals (NASDAQ:LBRX) was upgraded by analysts at Roth Capital to a "strong-buy" rating.MarketBeat
- LB Pharmaceuticals (NASDAQ:LBRX) is now covered by analysts at Roth Capital. They set a "buy" rating on the stock.MarketBeat
LBRX
Sec Filings
- 1/21/26 - Form SCHEDULE
- 1/21/26 - Form SCHEDULE
- 1/21/26 - Form SCHEDULE
- LBRX's page on the SEC website